A previous study investigated the activities of compounds demonstrated to be active in zebrafish embryo bioassays, in both zebrafish and mammalian cell lines [56].
In fact, not only PMX, as above reported, has demonstrated to be active as single agent but CPT-11 also has demonstrated activity, although modest, in pancreatic cancer (Wagener et al, 1995; Klapdor and Fenner, 2000; Pizzolato and Saltz, 2003).
In clinical trials, this anti-HER2 monoclonal antibody has been demonstrated to be active as a single agent and has been shown to improve survival when it is added to two standard chemotherapy regimens in patients with metastatic breast cancer.
A novel oral prodrug, AV-101 (l-4 chlorokynurenine), which, in the brain, is converted into one of the most potent and selective GlyB site antagonists of the NMDAR, has been demonstrated to be active in animal models of neuropathic pain.
Its essential oil (perilla oil) has been previously demonstrated to be active against S. aureus.
Interestingly, while ATG12 has not been found in kinetoplastids, autophagy has been demonstrated to be active in Leishmania spp. and play a key role in parasite virulence [59].
However, MREs in the CDS of a number of genes have recently been demonstrated to be active by in vitro reporter assays [43] [46].
ZFRs with catalytic domains from Tn3 resolvase and Gin invertase have been demonstrated to be active in human cell lines [15], [16], illustrating the potential applicability of these enzymes in mammals and other eukaryotic organisms.
Arabidopsis Group II enzymes were demonstrated to be active on IAA [ 13, 15].
Particularly, compound 17 was demonstrated to be active against an oseltamivir-resistant strain.
